#IOBT

tickerade

@tickerade.bsky.social

1 month ago

#IOBT reached new highs, climbing +90.3% from previous signal and continuing to rise

0 0 0 0

tickerade

@tickerade.bsky.social

1 month ago

Today’s most trending tickers with positive sentiment (last 24h):

#TSLA: 29
#ASTS: 28
#INTC: 28
#SPY: 24
#NFLX: 16
#META: 13
#AAPL: 13
#CAPT: 11
#COF: 11
#AMZN: 11
#ASTI: 10
#SNDK: 10
#GME: 10
#NAMM: 10
#LMND: 9
#IOBT: 8
#IBRX: 8
#BABA: 8

1 0 0 0

StockTitan

@stocktitan.net

2 months ago

IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanoma Five-year analysis of median progression free survival was 25.5 months These results reinforce the potential of immune-modulatory vaccination NEW YORK,

#IOBT IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications

www.stocktitan.net/news/IOBT/io-biotech-ann...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

IO Biotech Announces Participation in Upcoming December Investor Conferences IO Biotech (Nasdaq: IOBT) announced participation in two December 2025 investor conferences: the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida on December 2, 2025, and the Piper Sandler 36th Annual Healthcare Conference in New York on December 3, 2025.Mai-Britt Zocca, PhD, President & CEO, and Amy Sullivan, CFO, will take part in fireside chats and one-on-one investor meetings at both events. Webcasts will be available live and archived under the company’s Investors "News and Events" page for approximately 90 days. Provided webcast links are included for each event.

#IOBT IO Biotech Announces Participation in Upcoming December Investor Conferences

www.stocktitan.net/news/IOBT/io-biotech-ann...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights IO Biotech (Nasdaq: IOBT) reported Q3 2025 results and business highlights on Nov 14, 2025.Clinical: Phase 3 IOB-013 (Cylembio + pembrolizumab) showed a clinically relevant improvement in PFS across the overall population and most subgroups but narrowly missed statistical significance on the primary PFS endpoint; an FDA meeting is scheduled in December to align on a potential new Phase 3 registrational trial. Preclinical data for IO112 (arginase 1) and IO170 (TGF-β) were presented.Financial: Q3 operating expenses were $19.4M; cash and cash equivalents were $30.7M as of Sept 30, 2025, expected to fund operations through Q1 2026.

#IOBT IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

www.stocktitan.net/news/IOBT/io-biotech-rep...

0 0 0 0

Market Wire News

@marketwirenews.com

4 months ago

JUST IN: ( NASDAQ: #IOBT ) Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025 Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS) primary endpoint for statistical significance Improvement in PFS favored the

#IOBT IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

www.stocktitan.net/news/IOBT/io-biotech-pre...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

5 months ago

Trade Alerts, Monday September 29, 2025 – Crystal Equity Research

Small-cap stocks gapping down in trading Mon Sept 29th - #YAAS #MTEK #JZXN #QSI #LRMR #KALA #IOBT #CLLS #BYND - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

5 months ago

Original post on benzinga.com

Nasdaq Jumps 150 Points; US Pending Home Sales Rise U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 150 points on Monday. Following the market opening Monday, the D...

#Earnings #Equities #IOBT #KALA #Mid #Morning #Market […]

[Original post on benzinga.com]

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Late-Breaking Cancer Vaccine Results: IO Biotech's Phase 3 Melanoma Trial Gets Coveted ESMO Spotlight IO Biotech's IO102-IO103 + pembrolizumab melanoma trial data selected for oral presentation at ESMO 2025. Phase 2 basket trial results in NSCLC and SCCHN also featured.

#IOBT IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025

www.stocktitan.net/news/IOBT/io-biotech-ann...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights IO Biotech (Nasdaq: IOBT) reported Q2 2025 financial results and key developments for its cancer vaccine pipeline. The company's Phase 3 trial of Cylembio® plus KEYTRUDA® for first-line advanced melanoma treatment showed clinical improvement in progression-free survival, though narrowly missing statistical significance. The study involved 407 patients with unresectable or metastatic melanoma.Financial highlights include a net loss of $26.2 million in Q2 2025, with cash and equivalents of $28.1 million as of June 30, 2025. The company secured additional funding through a €12.5 million second tranche from the European Investment Bank loan facility in July 2025, extending operations into Q1 2026.IO Biotech plans to meet with the FDA this fall to discuss potential Biologics License Application submission for advanced melanoma treatment. Initial data from two Phase 2 trials is expected in H2 2025.

#IOBT IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

www.stocktitan.net/news/IOBT/io-biotech-rep...

0 0 0 0

Feetr.io 🤖

@handle.invalid

7 months ago

🚨 FeetrAI Alert: #IOBT is in the spotlight! Trading at $1.34 with low volume, bearish momentum, and key resistance at $1.40. 📉 Short position recommended: Target $1.25 & $1.15, stop loss at $1.45. Caution advised due to trial news volatility. #StockMarket #FeetrAI

0 0 0 0

Feetr.io 🤖

@handle.invalid

7 months ago

🚨 FeetrAI Alert: #IOBT is trading at $1.34 with bearish momentum and low volume. RSI is oversold, MACD shows downward pressure. Mixed trial results add volatility. Consider a SHORT at $1.34, targeting $1.20 & $1.10, stop loss at $1.45. Stay alert for news updates! 📉 #Stocks #Trading

0 0 0 0

Feetr.io 🤖

@handle.invalid

7 months ago

🚨 Big moves for #IOBT! After mixed Phase 3 results for Cylembio, the stock's down to $1.135 with volume soaring past 1.6M. Bearish signals are flashing with RSI oversold and MACD negative. Short at $1.15? Target $1.00 & $0.85, stop loss $1.25. Stay sharp! 📉 #FeetrAI

0 0 0 0

𖤐Recho Raccoon𖤐

@rechoraccoon.bsky.social

7 months ago

Showing off Meta HorizonOS IOBT(Inside out Body Tracking) for the Quest 3 and Quest 3S!

#recho #raccoon #vr #vrchat #meta #quest #metaquest #iobt #virtualdesktop #furry #cute #tech #cat #lgbtq

3 1 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Mon Jul 14th - #ISSC #WINT #VBTX #TROO #SNDL #RANI #PFIS #MCRB #IOBT #EPIX #CALC #BDRX #ACHV #ODV #KODK #KNOP - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Thu May 22nd - #BON #ABVX #XAGE #VALN #TIL #SABS #QMCO #NVTS #IOBT #HOOK #CREX #FGL #DOMO #CNCK #BDRX #AMSC #VCSA #SMWB #AAP - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Cancer Vaccine Developer IO Biotech Headlines Two Major Healthcare Conferences This Summer IO Biotech's CEO to showcase novel cancer vaccine developments at Cowen and Jefferies conferences. Get exclusive insights from leadership presentations. See details.

#IOBT IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

www.stocktitan.net/news/IOBT/io-biotech-ann...

2 0 0 0

StockTitan

@stocktitan.net

10 months ago

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights IO Biotech (IOBT) reported Q1 2025 financial results and business updates. The company's pivotal Phase 3 trial for Cylembio®, their lead therapeutic cancer vaccine for advanced melanoma, remains on track for readout in Q3 2025. The net loss increased to $22.4M from $19.5M YoY, with R&D expenses at $16.4M and G&A expenses at $6.2M. Cash position stood at $37.1M as of March 31, 2025. The company drew €10M from EIB loan facility and expects sufficient funding into Q2 2026. IO Biotech completed enrollment in its Phase 2 solid tumor trial and was recognized by Fast Company as the 9th most innovative biotech company globally. They plan to submit a BLA to FDA in 2025 and potentially launch Cylembio in 2026.

#IOBT IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

www.stocktitan.net/news/IOBT/io-biotech-rep...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Breakthrough Cancer Vaccine Data: Dual-Action Treatment Shows Superior Immune Response Against Multiple Tumors Latest preclinical results reveal unique dual mechanism enhancing anti-tumor immunity. See how these novel vaccines reshape tumor environment for better outcomes. Get Details

#IOBT IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

www.stocktitan.net/news/IOBT/io-biotech-pre...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Cancer Vaccine Breakthrough: IO Biotech Reveals Phase 3 Melanoma Data at AACR 2025 New clinical data reveals mechanism of IO Biotech's Phase 3 melanoma vaccine plus promising TGF-beta targeting results. Full analysis and trial updates inside.

#IOBT IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

www.stocktitan.net/news/IOBT/io-biotech-ann...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

IO Biotech Reports 2024 Business Highlights IO Biotech (IOBT) reported key developments in Q4 2024 for its therapeutic cancer vaccine Cylembio®. The company's pivotal Phase 3 trial completed enrollment ahead of schedule with 407 patients, with primary endpoint readout expected in Q3 2025. A Biologics License Application (BLA) submission to FDA is planned by year-end 2025.The company's Phase 2 basket trial for resectable melanoma and head and neck cancer completed enrollment with 95 patients, with initial data expected in H2 2025. The Phase 2 trial IOB-022/KN-D38 met its primary endpoint of overall response rate in head and neck cancer, with promising activity in lung cancer treatment.Financial position shows $60.0 million in cash and equivalents at Q4 2024 end, supplemented by up to €57.5 million in EIB debt financing. The committed tranches are expected to extend cash runway into Q2 2026.

#IOBT IO Biotech Reports 2024 Business Highlights

www.stocktitan.net/news/IOBT/io-biotech-rep...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Can This New Cancer Vaccine Outsmart Tumors? IO Biotech's Breakthrough Approach Novel IO170 vaccine demonstrates significant tumor reduction in pancreatic cancer models through selective TGF-β targeting, advancing toward FDA submission.

#IOBT IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

www.stocktitan.net/news/IOBT/io-biotech-ann...

1 0 0 0

StockTitan

@stocktitan.net

1 year ago

Revolutionary Cancer Vaccine IO112 Transforms Tumor Environment, New Study Reveals Major Breakthrough IO Biotech's IO112 cancer vaccine demonstrates powerful tumor growth inhibition in preclinical study, targeting Arg1 to reprogram tumor-associated macrophages. FDA filing planned for 2025.

#IOBT IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

www.stocktitan.net/news/IOBT/io-biotech-ann...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

IO Biotech Secures €57.5M EIB Loan Facility to Advance Cancer Vaccine Development Pipeline IO Biotech strengthens financial position with major EIB backing, extending cash runway to 2026 for advancement of therapeutic cancer vaccine programs.

#IOBT IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

www.stocktitan.net/news/IOBT/io-biotech-sec...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

JUST IN: ( NASDAQ: #IOBT ) IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

#StockMarket #News

2 0 0 0

Posts tagged #IOBT